Kairos Pharma Reports Promising Phase 2 Results for Prostate Cancer Treatment ENV105
Kairos Pharma's ENV105 demonstrates 86% clinical benefit rate in advanced metastatic prostate cancer patients when combined with standard therapy, potentially addressing critical treatment resistance challenges in oncology.
Kairos Pharma Ltd. (NYSE American: KAPA) has released a shareholder letter from CEO John Yu, M.D., detailing significant clinical progress and outlining key 2026 milestones for the company's cancer therapeutics pipeline. The clinical-stage biopharmaceutical company reported positive interim safety and efficacy results from its Phase 2 trial of ENV105 in combination with apalutamide for advanced metastatic prostate cancer.
The interim data showed clinical benefit in 86% of treated patients, with durable progression-free survival and no dose-limiting toxicities observed. These findings, presented at the European Society for Medical Oncologists Meeting, suggest ENV105 may extend the effectiveness of standard care while maintaining strong tolerability. The company continues patient recruitment, with enrollment expected to reach 100 across leading U.S. cancer centers.
ENV105 represents a novel approach to cancer treatment by targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. According to company information available at https://ibn.fm/KAPA, elevation of CD105 in response to standard therapy often results in resistance and disease relapse. The antibody aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
Beyond the prostate cancer program, ENV105 is also in a Phase 1 trial for lung cancer, addressing significant unmet medical needs in both indications. The company's approach utilizes structural biology to overcome drug resistance and immune suppression in cancer, positioning its pipeline to potentially transform treatment outcomes for patients who develop resistance to current standard therapies.
The clinical progress comes as Kairos Pharma works to establish itself at the forefront of oncology therapeutics. The full shareholder letter and additional company updates can be accessed through the company's newsroom at https://ibn.fm/KAPA. The positive interim results provide important validation for the company's scientific approach and suggest potential for ENV105 to become a meaningful addition to the cancer treatment landscape, particularly for patients facing limited options after developing resistance to existing therapies.